GCCL Strengthens Asia-Pacific Presence at Asia Bio Partnering Forum 2026

YONGIN, South Korea , Sept. 8, 2026 /PRNewswire/ -- GCCL (Global Clinical Central Lab), a South Korea-based leading provider of clinical trial sample analysis, announced its participation as a Platinum Sponsor at Asia Bio Partnering Forum 2026 (ABP 2026), held in Singapore from August 31 to September 2.

Through a series of partnering meetings with global pharmaceutical and biotechnology companies, contract research organizations (CROs) and regional stakeholders, GCCL explored opportunities to expand its clinical sample analysis and assay development services across the Asia-Pacific region.

The company engaged with drug developers working across a broad range of therapeutic modalities, including mRNA and nucleic acid therapeutics, radiopharmaceuticals and antibody-based therapies. These discussions focused on evolving analytical requirements in global clinical development and potential opportunities for collaboration.

GCCL also met with executives from global CROs and Singapore-based pharmaceutical, diagnostics and clinical trial service companies to discuss existing partnerships and opportunities for further collaboration. In addition, the company engaged with a Singapore government-affiliated economic development organization to explore ways to support local biotech companies and strengthen connections within the regional life sciences ecosystem.

As a Platinum Sponsor, GCCL sponsored the official ABP 2026 Welcome Reception. Yoo-Hwa Choi, Head of Business Operations at GCCL, delivered welcome remarks and highlighted the company's capabilities in clinical sample analysis and its commitment to supporting global drug development.

At its exhibition booth, GCCL showcased its integrated Central Lab, Bioanalytical Lab and R&D Lab capabilities, which support clinical development from early- through late-stage trials. The company also held partnering discussions with pharmaceutical and biotechnology companies and related organizations from Korea, China, Japan, Singapore, Vietnam and Europe.

"ABP 2026 provided an important opportunity to engage directly with drug developers and global partners across the Asia-Pacific region and better understand their evolving analytical needs across increasingly diverse therapeutic modalities," said Yoo-Hwa Choi, Head of Business Operations at GCCL. "We will continue to build on these relationships and expand collaboration with global CROs and regional biotech companies as we strengthen GCCL's role as a trusted clinical development partner in Asia-Pacific."

ABP 2026 brought together approximately 650 pharmaceutical and biotechnology industry professionals, investors and life sciences stakeholders, with approximately 2,500 one-on-one partnering meetings held during the event.

About GCCL (Global Clinical Central Lab)

GCCL, a subsidiary of the GC Group, is a leading clinical trial sample analysis provider offering an integrated "one-stop lab solution" with central, bioanalysis, and BSL-3 labs under one system. With tailored solutions, GCCL delivers precise and efficient analytical services across all phases of clinical trials, solidifying its position as a trusted partner in new drug development. Leveraging advanced platforms and LIMS, the company supports partners across Asia and beyond with customized and compliant solutions. In recognition of its leadership, GCCL recently received Frost & Sullivan's 2025 Best Practices Customer Value Leadership Award in the Asia-Pacific clinical sample analysis services industry. For more details, visit: www.eng.gccl.co.kr.

GC Corporation Contacts (Media)

Sohee Kim
[email protected]

Yelin Jun
[email protected]

Yoonjae Na
[email protected]

SOURCE GCCL